A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 129,869 shares of BTAI stock, worth $45,454. This represents 0.0% of its overall portfolio holdings.

Number of Shares
129,869
Holding current value
$45,454
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$0.53 - $1.34 $68,830 - $174,024
129,869 New
129,869 $79,000
Q1 2024

May 13, 2024

BUY
$1.95 - $4.04 $46,228 - $95,776
23,707 New
23,707 $67,000
Q1 2023

May 12, 2023

BUY
$17.7 - $33.24 $1.66 Million - $3.12 Million
94,000 New
94,000 $1.75 Million
Q3 2022

Nov 14, 2022

SELL
$11.19 - $17.89 $224,919 - $359,589
-20,100 Reduced 36.15%
35,500 $420,000
Q2 2022

Aug 12, 2022

BUY
$9.03 - $21.55 $332,304 - $793,040
36,800 Added 195.74%
55,600 $734,000
Q1 2022

May 13, 2022

BUY
$15.0 - $22.83 $282,000 - $429,203
18,800 New
18,800 $393,000
Q3 2020

Nov 13, 2020

SELL
$37.44 - $64.63 $5.83 Million - $10.1 Million
-155,600 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$17.62 - $58.71 $1.46 Million - $4.88 Million
83,100 Added 114.62%
155,600 $8.25 Million
Q1 2020

May 14, 2020

SELL
$12.26 - $41.14 $29,424 - $98,736
-2,400 Reduced 3.2%
72,500 $1.62 Million
Q4 2019

Feb 13, 2020

SELL
$4.05 - $14.61 $11,340 - $40,908
-2,800 Reduced 3.6%
74,900 $1.09 Million
Q3 2019

Nov 13, 2019

BUY
$7.04 - $11.77 $42,944 - $71,797
6,100 Added 8.52%
77,700 $547,000
Q2 2019

Aug 12, 2019

BUY
$8.99 - $11.79 $240,932 - $315,972
26,800 Added 59.82%
71,600 $785,000
Q1 2019

May 14, 2019

BUY
$3.49 - $10.47 $156,352 - $469,056
44,800 New
44,800 $443,000

Others Institutions Holding BTAI

About BioXcel Therapeutics, Inc.


  • Ticker BTAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,022,500
  • Market Cap $9.81M
  • Description
  • BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...
More about BTAI
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.